Profile data is unavailable for this security.
About the company
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-68.46m
- Incorporated2021
- Employees59.00
- LocationRezolute Inc275 Shoreline Drive, Suite 500REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 206-4507
- Fax+1 (302) 636-5454
- Websitehttps://www.rezolutebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | 88.46m | -112.77m | 299.13m | 337.00 | -- | 4.92 | -- | 3.38 | -1.19 | -1.19 | 0.9296 | 0.6265 | 0.3051 | -- | 7.27 | 268,066.70 | -38.89 | -40.70 | -52.75 | -47.72 | -- | -- | -127.48 | -233.49 | -- | -13.14 | 0.4916 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 302.52m | 203.00 | -- | 0.559 | -- | 1.59 | -0.2824 | -0.2824 | 3.29 | 9.29 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | -- | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 306.19m | 175.00 | -- | 1.20 | -- | 25.10 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Taysha Gene Therapies Inc | 12.87m | -114.34m | 307.41m | 52.00 | -- | 2.77 | -- | 23.88 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| AVITA Medical Inc | 60.04m | -57.32m | 310.58m | 207.00 | -- | 25.62 | -- | 5.17 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 312.65m | 161.00 | -- | 1.40 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 315.27m | 123.00 | -- | 37.41 | -- | 10.53 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| AC Immune SA | 17.69m | -69.13m | 316.61m | 133.00 | -- | 2.25 | -- | 17.89 | -0.7332 | -0.7332 | 0.1911 | 1.42 | 0.0787 | -- | 28.76 | 133,041.40 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Tango Therapeutics Inc | 43.38m | -123.40m | 316.88m | 140.00 | -- | 1.38 | -- | 7.30 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 318.40m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Rezolute Inc | 0.00 | -68.46m | 323.32m | 59.00 | -- | 2.46 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.87m | 328.01m | 10.00 | -- | 3.34 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 330.10m | 57.00 | -- | 1.26 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Codexis Inc | 64.45m | -62.09m | 332.02m | 174.00 | -- | 4.52 | -- | 5.15 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| iTeos Therapeutics Inc | 35.00m | -108.14m | 338.56m | 157.00 | -- | 0.51 | -- | 9.67 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 349.30m | 33.00 | -- | 1.52 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Rezolute Inc's reporting currency: US Dollar USD
50.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 30 Jun 2024 | 11.28m | 20.37% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 2.99m | 5.40% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 2.06m | 3.73% |
| Affinity Asset Advisors LLCas of 30 Jun 2024 | 1.85m | 3.34% |
| Blackstone Alternative Asset Management LPas of 30 Jun 2024 | 1.74m | 3.15% |
| Sphera Funds Management Ltd.as of 30 Jun 2024 | 1.71m | 3.09% |
| Altium Capital Management LPas of 30 Jun 2024 | 1.70m | 3.07% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.61m | 2.90% |
| Ghost Tree Capital LLCas of 30 Jun 2024 | 1.42m | 2.57% |
| Caxton Corp.as of 30 Jun 2024 | 1.32m | 2.38% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
